December 11, 2023 • 2hr 51min

Dr. Karen Parker: The Causes & Treatments for Autism

Huberman Lab

In this episode, Dr. Andrew Huberman interviews Dr. Karen Parker, professor of psychiatry and director of the Social Neurosciences Research Program at Stanford University School of Medicine. They discuss the biology of social connections and bonding, with a focus on autism spectrum disorders. Dr. Parker explains current understanding of what autism is, why rates have increased, and both current and emerging treatments. The conversation covers the roles of neuropeptides like oxytocin and vasopressin, animal models of social impairment, clinical trials, and future directions for autism research.

0:00

-0:00

Key Takeaways

The incidence of autism has increased dramatically in recent years, now affecting 1 in 36 children in the US
Autism is a behavioral diagnosis characterized by pervasive social interaction challenges and restricted repetitive behaviors
There is no single known cause of autism - it likely results from a complex interaction of genetic and environmental factors
Early intervention and behavioral therapies can be helpful, but there are currently no FDA-approved medications to treat the core symptoms of autism
Dr. Parker's research has identified low levels of the neuropeptide vasopressin in the cerebrospinal fluid of children with autism
In a small clinical trial, intranasal vasopressin administration improved social functioning in children with autism
The gut microbiome may play a role in regulating vasopressin and oxytocin levels in the brain, potentially impacting social behavior
More research is needed to fully understand the biological basis of autism and develop targeted treatments

Introduction

In this episode, Dr. Andrew Huberman interviews Dr. Karen Parker, professor of psychiatry and director of the Social Neurosciences Research Program at Stanford University School of Medicine. They discuss the biology of social connections and bonding, with a focus on autism spectrum disorders. Dr. Parker explains current understanding of what autism is, why rates have increased, and both current and emerging treatments. The conversation covers the roles of neuropeptides like oxytocin and vasopressin, animal models of social impairment, clinical trials, and future directions for autism research.

Topics Discussed

Autism Prevalence and Diagnosis (6:41)

Dr. Parker explains that autism now affects 1 in 36 children in the US, a dramatic increase from previous estimates. The disorder is more prevalent in males, with 3-4 boys diagnosed for every 1 girl. Autism is diagnosed behaviorally by expert clinicians, typically psychiatrists or psychologists. The two core features they look for are:

Pervasive social interaction challenges
Presence of restricted repetitive behaviors

Many individuals with autism also experience anxiety, sensory challenges, seizures, and sleep disorders. Dr. Parker emphasizes that autism presents differently in each person - "if you've met one person with autism, you've met one person with autism."

Early Intervention and Heritability (10:41)

Early diagnosis and intervention are important, as behavioral therapies may be more effective at younger ages when the brain is more plastic. However, long wait times to see specialists can delay diagnosis. Dr. Parker notes that autism is highly heritable, with genetics accounting for 40-80% of autism risk. Having one child with autism increases the likelihood of subsequent children also being diagnosed.

Autism Spectrum and Research Challenges (13:00)

The discussion explores whether autism should be viewed as a single spectrum or multiple intersecting spectra of traits. Dr. Parker explains that without understanding the underlying biology, it's difficult to determine how to categorize the diverse presentations. Studying autism in humans is challenging due to limitations in accessing brain tissue/fluids and difficulties getting severely affected individuals into brain scanners. Animal models, particularly non-human primates, may help overcome some research barriers.

Environmental Influences and Risk Factors (21:29)

While genetics play a major role, environmental factors also contribute to autism risk. Some identified risk factors include:

Advanced parental age
Premature birth
Maternal illness during pregnancy

However, Dr. Parker notes it's difficult to definitively pin down environmental causes due to the genetic heterogeneity of autism. More research is needed to understand gene-environment interactions.

Oxytocin, Vasopressin and Social Behavior (31:26)

Dr. Parker discusses the neuropeptides oxytocin and vasopressin, which play important roles in social bonding and behavior across species. Key points:

Oxytocin and vasopressin are structurally similar and can bind to each other's receptors
They were initially studied for peripheral effects (e.g. uterine contractions, blood pressure regulation) before their roles in the brain were discovered
Animal studies show vasopressin is critical for male social behavior, pair bonding, and paternal care
The effects are species-specific - what causes aggression in one species may promote affiliation in another

Oxytocin Research in Autism (43:24)

Dr. Parker describes research on oxytocin as a potential treatment for autism:

Early single-dose studies showed promise for improving social cognition
Her team found lower baseline blood oxytocin correlated with greater benefit from oxytocin treatment
However, a large multi-site trial showed no overall benefit of oxytocin for autism
Oxytocin research has largely been abandoned due to lack of funding after negative results

Dr. Parker believes oxytocin may still benefit a subset of individuals with autism, but more research is needed to identify responders.

Vasopressin and Autism (55:16)

Dr. Parker's research has focused on vasopressin as a more promising target for autism treatment:

Her team found low cerebrospinal fluid (CSF) vasopressin levels in monkeys with naturally low social behavior
This was replicated in children with autism - CSF vasopressin levels correlated with social symptom severity
Low CSF vasopressin was detectable in infants before autism symptoms emerged
In a small clinical trial, intranasal vasopressin improved social functioning in children with autism

A larger follow-up trial is underway to replicate these promising initial results.

Neuroplasticity and Early Intervention (1:06:30)

The discussion explores the importance of early intervention to leverage neuroplasticity in young children with autism. Key points:

Behavioral therapies may be most effective at younger ages when the brain is more plastic
Long wait times for diagnosis can delay critical early interventions
There's a need for better screening tools and biomarkers to identify at-risk children earlier
Vasopressin treatment, if proven effective, could potentially alter developmental trajectories if given early

Gut Microbiome and Neuropeptides (2:26:35)

Recent research suggests the gut microbiome may influence oxytocin and vasopressin levels in the brain:

Mouse studies show probiotics can normalize social behavior and increase hypothalamic oxytocin/vasopressin
The vagus nerve provides a direct connection between the gut and brain regions producing these neuropeptides
Severing the vagus nerve prevents the behavioral effects of probiotic treatment in mice
This provides a potential mechanism linking gut health to social behavior

Vasopressin Pathways and Future Research (2:34:52)

Dr. Parker discusses next steps for vasopressin research in autism:

Examining postmortem brain tissue to look at vasopressin-producing cells and gene expression
Investigating if vasopressin deficiency causes excessive urination or bedwetting in some children with autism
Exploring alternative ways to boost vasopressin naturally (e.g. vagus nerve stimulation)
Identifying subgroups of individuals most likely to benefit from vasopressin treatment

She emphasizes the need for more funding to pursue these promising research directions.

Vaccines and Autism (2:43:00)

The episode concludes with a discussion of the debunked link between vaccines and autism:

The original study claiming a vaccine-autism link was found to be fraudulent and retracted
Numerous subsequent studies have found no connection between vaccines and autism
The vaccine controversy diverted significant research funding away from other important areas of autism research
There is a need to better understand potential immune system involvement in some cases of autism, separate from vaccine effects

Conclusion

This wide-ranging conversation highlights the complexity of autism and the challenges in studying and treating this heterogeneous disorder. Dr. Parker's research on vasopressin offers a promising new direction for understanding the biological basis of social impairments in autism and developing targeted treatments. While much remains unknown, continued research into the roles of neuropeptides, the gut microbiome, and early interventions may lead to improved outcomes for individuals with autism spectrum disorders.